Skip Navigation

JNCI Journal of the National Cancer Institute 1989 81(19):1464-1471; doi:10.1093/jnci/81.19.1464
© 1989 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Mangioni, C.
Right arrow Articles by Marsoni, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mangioni, C.
Right arrow Articles by Marsoni, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 81, No. 19, 1464-1471, October 4, 1989
© 1989 Oxford University Press

Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin

C. Mangioni, G. Bolis, S. Pecorelli, K. Bragman, A. Epis, G. Favalli, A. Gambino, F. Landoni, M. Presti, W. Torri, L. Vassena, F. Zanaboni, S. Marsoni*

Clinica Ostetrico-Ginecologica, Ospedale S. Gerardo Milan, Italy
III Clinica Ostetrico-Ginecologica), Università di Milano Milan, Italy
Clinica Ostetrico-Ginecologica, Università di Brescia Brescia, Italy
Pharmaceutical Research and Development Bristol-Myers, Brussels, Belgium
Istituto di Ricerche Farmacologiche Mario Negri Milan, Italy

*Correspondence to: Dr. S. Marsoni, Istituto M. Negri, Via Eritrea 62, Milan 20157, Italy.

The aim of this multicenter randomized trial was to compare carboplatin (400 mg/m2) and cisplatin (100 mg/m2) in patients with untreated advanced epithelial ovarian cancer. Toxicity and treatment efficacy assessed by pathological response rate, progression-free survival, and survival were the endpoints of the study. One hundred seventy-three patients with advanced epithelial ovarian cancer, F.I.G.O. (International Federation of Gynecology and Obstetrics) stages III and IV were accrued in the trial. The median follow-up time was 15 months (maximum, 34); three patients in each treatment arm were not eligible (four, nonepithelial ovarian cancer type; one, no data, and one, stage II). Patient characteristics were similar in the two groups. In the carboplatin-treatment arm, the overall pathological response rate was 57.3% and the complete pathological response rate was 26.8%. In the cisplatin-treatment arm, the overall pathological response rate was 71.6% and the complete pathological response rate was 24.7%. There was no statistical difference in the two arms in survival or progression-free survival. Cisplatin was more nephrotoxic while carboplatin induced a higher degree of myelosuppression, especially thrombocytopenia; however, severe hematological toxicity was seldom observed. Carboplatin is a cisplatin analog with definite activity in ovarian cancer, but it is not more active than the parent compound. Because of less nonhematological toxicity, carboplatin is undoubtedly a useful substitute in patients who cannot be given cisplatin. Further experience is needed to indicate whether or not carboplatin should completely displace cisplatin in the clinical treatment of ovarian cancer. [J Natl Cancer Inst 81: 1464–1471, 1989]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
J. Clin. Oncol., March 1, 2002; 20(5): 1248 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. S. Alberts and R. T. Dorr
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
Oncologist, February 1, 1998; 3(1): 15 - 34.
[Abstract] [Full Text]

Home page
 BloodHome page
R. L. Basser, J. E.J. Rasko, K. Clarke, J. Cebon, M. D. Green, A. P. Grigg, J. Zalcberg, B. Cohen, J. O'Byrne, D. M. Menchaca, et al.
Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer
Blood, May 1, 1997; 89(9): 3118 - 3128.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.